PCRX — Pacira BioSciences, Inc. stock price, charts and financials

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA

Latest market price

24.35

-0.67-2.68%

Overview Short InterestFilings

PCRXQT53Pacira BioSciences, Inc.·NASDAQ

Overview Short InterestFilings

24.35-2.68%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

COLL-6.94%$27.43 AMPH-3.75%$20.00 CRON-2.42%$3.02 ETON-2.16%$43.63 ALVO-1.18%$3.77 EVO+4.00%$2.08 IRWD-4.86%$4.11 PAHC-0.73%$34.04

Snapshot

Index	-	P/E	71.06	EPS (ttm)	0.35	Insider Own	6.97%	Shs Outstand	39.34M	Perf Week	-5.26%

Market Cap	984.16M	Forward P/E	7.07	EPS next Y	3.54	Insider Trans	-1.54%	Shs Float	37.68M	Perf Month	-1.88%

Enterprise Value	1.19B	PEG	1.10	EPS next Q	-	Inst Own	-	Short Float	18.48%	Perf Quarter	5.84%

Income	14.57M	P/S	1.32	EPS this Y	2336.38%	Inst Trans	-	Short Ratio	13.32	Perf Half Y	22.89%

Sales	746.15M	P/B	1.47	EPS next Y	21.13%	ROA	1.18%	Short Interest	6.96M	Perf YTD	-3.32%

Book/sh	-	P/C	4.63	EPS next 5Y	13.61%	ROE	2.13%	52W High	26.92 -9.54%	Perf Year	11.70%

Cash/sh	-	P/FCF	4.86	EPS past 3/5Y	-22.22% -45.51%	ROIC	1.35%	52W Low	18.30 33.09%	Perf 3Y	-31.84%

Dividend Est.	-	EV/EBITDA	10.37	Sales past 3/5Y	2.87% 11.04%	Gross Margin	79.21%	Volatility	4.95% 3.67%	Perf 5Y	-57.56%

Dividend TTM	-	EV/Sales	1.60	EPS Y/Y TTM	105.58%	Oper. Margin	2.47%	ATR (14)	1.08	Perf 10Y	-33.23%

Dividend Ex-Date	-	Quick Ratio	3.94	Sales Y/Y TTM	4.85%	Profit Margin	1.96%	RSI (14)	45.73	Recom	2.69

Dividend Gr. 3/5Y	-	Current Ratio	5.04	EPS Q/Q	-3.23%	SMA20	-3.53%	Beta	0.24	Target Price	28.50

Payout	0.00%	Debt/Eq	0.61	Sales Q/Q	4.73%	SMA50	1.42%	Rel Volume	1.12	Prev Close	25.02

Employees	829	LT Debt/Eq	0.64	Earnings	Nov 05	SMA200	6.20%	Avg Volume	540.32K	Price	24.35

IPO Date	Feb 03, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.57% 3.25%	Net Debt/EBITDA	1.80	Volume	603,210	Change	-2.68%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-05-26	Reiterated	RBC Capital	Sector Perform	$25
May-01-26	Reiterated	Needham	Buy	$63 → $32
Dec-08-25	Initiated	Barclays	Equal Weight	$24 → $27
Feb-28-25	Reiterated	HC Wainwright & Co.	Buy	$57 → $48
Feb-28-25	Reiterated	Barclays	Overweight	$24
Jan-30-25	Upgrade	Truist Securities	Sell → Hold	$8.00 → $25
Nov-07-24	Reiterated	Piper Sandler	Overweight	$42 → $12
Sep-24-24	Reiterated	Jefferies	Buy	$36 → $18
Aug-13-24	Downgrade	Truist Securities	Buy → Sell	$8.00
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight

Latest News

Aug-07-26

Aug-07-2608:00AM

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Aug-06-26

Aug-06-2608:00AM

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseasesglobenewswire.com

Aug-05-26

Aug-05-2602:36PM

Pacira BioSciences, Inc. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha

01:21PM

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cutzacks.com

Aug-04-26

Aug-04-2609:30PM

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcriptseekingalpha.com

06:41PM

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimateszacks.com

04:01PM

Pacira BioSciences Reports Second Quarter 2026 Financial Resultsglobenewswire.com

Aug-03-26

Aug-03-2605:18AM

First Trust Advisors LP Grows Position in Pacira BioSciences, Inc. $PCRXdefenseworld.net

Jul-27-26

Jul-27-2608:03AM

Pacira BioSciences Successfully Transitions PCRX-201 To A Scalable Commercial Manufacturing Process In The U.S.; Topline Data From Part A Of Phase 2 ASCEND Study Remains On Track For End Of 2026Benzinga

08:00AM

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Processglobenewswire.com

Jul-26-26

Jul-26-2601:59AM

Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $29.40defenseworld.net

Jul-22-26

Jul-22-2608:00AM

Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026globenewswire.com

Jul-08-26

Jul-08-2608:00AM

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Jul-01-26

Jul-01-2610:30AM

Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Dealzacks.com

08:15AM

HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price TargetBenzinga

Company

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	746	726	701	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	154	150	170	—	—	—	—	—	—
Gross Profit	591	577	531	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	380	369	294	—	—	—	—	—	—
Research and Development	121	117	82	—	—	—	—	—	—
Other Operating Expense	71	57	228	—	—	—	—	—	—
Operating Income	18	33	-73	—	—	—	—	—	—
Interest Expense	14	15	17	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	14	-2	27	—	—	—	—	—	—
Net Income Before Taxes	19	17	-63	—	—	—	—	—	—
Income Taxes	3	10	36	—	—	—	—	—	—
Consolidated Net Income	15	7	-100	—	—	—	—	—	—
Net Income From Continuing Operations	15	7	-100	—	—	—	—	—	—
Net Income	15	7	-100	—	—	—	—	—	—
EPS (Recurring)	0.35	0.16	-2.15	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.35	0.16	-2.15	—	—	—	—	—	—
EPS (Diluted)	0.35	0.16	-2.15	—	—	—	—	—	—
EBITDA	115	123	29	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	69.57	161.75	—	—	—	—	—	—	—
Price To Sales Ratio	1.27	1.60	1.24	—	—	—	—	—	—
Gross Margin	79.22	79.48	75.75	—	—	—	—	—	—
Operating Margin	2.41	4.55	-10.41	—	—	—	—	—	—
Net Margin	2.01	0.96	-14.27	—	—	—	—	—	—
Shares Outstanding	39	45	46	—	—	—	—	—	—
Market Capitalization	950	1,165	867	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RIKER LAUREN	Senior Vice President, Finance	Jun 11 '26	Sale	23.50	6,115	143,703	62,284	Jun 12
WILLIAMS KRISTEN	Chief Administrative Officer	Jun 04 '26	Sale	22.27	10,259	228,468	167,062	Jun 05
Cross Shawn	Chief Financial Officer	Apr 23 '26	Option Exercise	16.45	12,941	212,879	118,282	Apr 24
Cross Shawn	Chief Financial Officer	Apr 23 '26	Sale	25.16	12,941	325,596	105,341	Apr 24
Cross Shawn	Chief Financial Officer	Apr 22 '26	Sale	25.01	1,500	37,515	105,341	Apr 22
Cross Shawn	Chief Financial Officer	Apr 22 '26	Option Exercise	16.45	1,500	24,675	106,841	Apr 22
Cross Shawn	Chief Financial Officer	Apr 21 '26	Option Exercise	16.45	2,845	46,800	108,186	Apr 22
Cross Shawn	Chief Financial Officer	Apr 20 '26	Sale	25.14	7,714	193,930	105,341	Apr 22
Cross Shawn	Chief Financial Officer	Apr 20 '26	Option Exercise	16.45	7,714	126,895	113,055	Apr 22
SLONIN JONATHAN	Chief Medical Officer	Mar 17 '26	Sale	22.82	3,261	74,416	223,640	Mar 19
Froimson Mark	Director	Mar 17 '26	Sale	21.81	500	10,905	20,136	Mar 19
RIKER LAUREN	Senior Vice President, Finance	Feb 02 '26	Sale	20.81	4,000	83,240	52,313	Feb 03
WILLIAMS KRISTEN	Chief Administrative Officer	Feb 02 '26	Sale	20.53	13,137	269,703	131,303	Feb 03
RIKER LAUREN	Senior Vice President, Finance	Jan 05 '26	Sale	24.24	1,416	34,324	59,064	Jan 06
Cross Shawn	Chief Financial Officer	Dec 10 '25	Sale	25.14	9,104	228,875	56,250	Dec 11

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.